The Urticaria Pigmentosa (Mastocytosis, Mastocytoma) drugs in development market research report provides comprehensive information on the therapeutics under development for Urticaria Pigmentosa (Mastocytosis, Mastocytoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Urticaria Pigmentosa (Mastocytosis, Mastocytoma). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Urticaria Pigmentosa (Mastocytosis, Mastocytoma) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Urticaria Pigmentosa (Mastocytosis, Mastocytoma) by seven companies/universities/institutes. The top development phase for Urticaria Pigmentosa (Mastocytosis, Mastocytoma) is preclinical with six drugs in that stage. The Urticaria Pigmentosa (Mastocytosis, Mastocytoma) pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Urticaria Pigmentosa (Mastocytosis, Mastocytoma) pipeline products market are: Medical University of Vienna, Merck and Sixal.
The key targets in the Urticaria Pigmentosa (Mastocytosis, Mastocytoma) pipeline products market include Interleukin 12 (IL12), Histamine H1 Receptor (HRH1), and Carbonic Anhydrase 1 (Carbonate Dehydratase I or Carbonic Anhydrase B or Carbonic Anhydrase I or CAB or CA1 or EC 4.2.1.1).
The key mechanisms of action in the Urticaria Pigmentosa (Mastocytosis, Mastocytoma) pipeline product include Histamine H1 Receptor (HRH1) Antagonist with one drug in Preclinical. The Urticaria Pigmentosa (Mastocytosis, Mastocytoma) pipeline products include two routes of administration with the top ROA being Oral and five key molecule types in the Urticaria Pigmentosa (Mastocytosis, Mastocytoma) pipeline products market including Small Molecule, and Recombinant Vector Vaccine.
Urticaria Pigmentosa (Mastocytosis, Mastocytoma) overview
Urticaria pigmentosa, or mastocytosis of the skin, is a condition characterized by a rash of reddish-brown spots called mastocytomas. These are accumulations of mast cells that have the same genetic mutation, one of several potential mutations in the KIT gene. Symptoms include itching, hives, wheezing, diarrhea and anaphylaxis. Diagnosing doctors look for Darier sign (raised bumps due to rubbing skin patches) and suggest skin biopsy and blood tests. Bone marrow biopsy may be suggested in adults. Avoiding histamine release triggers like insect bites and stings, exposure to extreme temperature, and rubbing the skin can be helpful. Medications like antihistamines can be used to relieve the symptoms.
For a complete picture of Urticaria Pigmentosa (Mastocytosis, Mastocytoma)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
